147 related articles for article (PubMed ID: 21149634)
1. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival.
Steinbrunn T; Stühmer T; Gattenlöhner S; Rosenwald A; Mottok A; Unzicker C; Einsele H; Chatterjee M; Bargou RC
Blood; 2011 Feb; 117(6):1998-2004. PubMed ID: 21149634
[TBL] [Abstract][Full Text] [Related]
2. Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.
Müller E; Bauer S; Stühmer T; Mottok A; Scholz CJ; Steinbrunn T; Brünnert D; Brandl A; Schraud H; Kreßmann S; Beilhack A; Rosenwald A; Bargou RC; Chatterjee M
Leukemia; 2017 Apr; 31(4):922-933. PubMed ID: 27686868
[TBL] [Abstract][Full Text] [Related]
3. Downstream effectors of oncogenic ras in multiple myeloma cells.
Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
[TBL] [Abstract][Full Text] [Related]
4. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Steinbrunn T; Stühmer T; Sayehli C; Chatterjee M; Einsele H; Bargou RC
Br J Haematol; 2012 Nov; 159(4):430-40. PubMed ID: 22985491
[TBL] [Abstract][Full Text] [Related]
5. RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.
Seibold M; Stühmer T; Kremer N; Mottok A; Scholz CJ; Schlosser A; Leich E; Holzgrabe U; Brünnert D; Barrio S; Kortüm MK; Solimando AG; Chatterjee M; Einsele H; Rosenwald A; Bargou RC; Steinbrunn T
Haematologica; 2020 Sep; 105(9):2316-2326. PubMed ID: 33054056
[TBL] [Abstract][Full Text] [Related]
6. Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.
Hausmann S; Brandt E; Köchel C; Einsele H; Bargou RC; Seggewiss-Bernhardt R; Stühmer T
PLoS One; 2015; 10(4):e0122689. PubMed ID: 25837824
[TBL] [Abstract][Full Text] [Related]
7. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity.
Toulany M; Baumann M; Rodemann HP
Mol Cancer Res; 2007 Aug; 5(8):863-72. PubMed ID: 17699110
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors.
Zhang J; Lodish HF
Blood; 2004 Sep; 104(6):1679-87. PubMed ID: 15166036
[TBL] [Abstract][Full Text] [Related]
9. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.
Kim IA; Bae SS; Fernandes A; Wu J; Muschel RJ; McKenna WG; Birnbaum MJ; Bernhard EJ
Cancer Res; 2005 Sep; 65(17):7902-10. PubMed ID: 16140961
[TBL] [Abstract][Full Text] [Related]
12. Statins inhibited the MIP-1α expression via inhibition of Ras/ERK and Ras/Akt pathways in myeloma cells.
Tsubaki M; Mashimo K; Takeda T; Kino T; Fujita A; Itoh T; Imano M; Sakaguchi K; Satou T; Nishida S
Biomed Pharmacother; 2016 Mar; 78():23-29. PubMed ID: 26898421
[TBL] [Abstract][Full Text] [Related]
13. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival.
Carón RW; Yacoub A; Li M; Zhu X; Mitchell C; Hong Y; Hawkins W; Sasazuki T; Shirasawa S; Kozikowski AP; Dennis PA; Hagan MP; Grant S; Dent P
Mol Cancer Ther; 2005 Feb; 4(2):257-70. PubMed ID: 15713897
[TBL] [Abstract][Full Text] [Related]
14. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.
Lee S; Heinrich EL; Lu J; Lee W; Choi AH; Luu C; Chung V; Fakih M; Kim J
Pancreas; 2016 Feb; 45(2):286-92. PubMed ID: 26262587
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.
Shi Y; Gera J; Hsu JH; Van Ness B; Lichtenstein A
Mol Cancer Ther; 2003 Jun; 2(6):563-72. PubMed ID: 12813136
[TBL] [Abstract][Full Text] [Related]
16. K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs.
Minjgee M; Toulany M; Kehlbach R; Giehl K; Rodemann HP
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1506-14. PubMed ID: 21985943
[TBL] [Abstract][Full Text] [Related]
17. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.
Lin YT; Way GP; Barwick BG; Mariano MC; Marcoulis M; Ferguson ID; Driessen C; Boise LH; Greene CS; Wiita AP
Blood Adv; 2019 Nov; 3(21):3214-3227. PubMed ID: 31698452
[TBL] [Abstract][Full Text] [Related]
18. Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma.
Li S; Fu J; Yang J; Ma H; Bhutani D; Mapara MY; Marcireau C; Lentzsch S
Blood; 2021 Apr; 137(13):1754-1764. PubMed ID: 33036022
[TBL] [Abstract][Full Text] [Related]
19. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
20. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
